CME Group is currently facing regulatory challenges as it prepares to sue the Commodity Futures Trading Commission (CFTC) over its approval of perpetual futures contracts. Despite this, Keefe, Bruyette & Woods has upgraded CME's stock rating from market perform to outperform, maintaining a price target of $305, which suggests a potential upside of 21% from its recent closing price.
Analyst Chris Allen noted that the recent decline in CME's stock, which has dropped nearly 8% year-to-date and 17% in the past month, is largely due to fears surrounding perpetual futures, a financial derivative that allows traders to speculate on asset prices without expiration dates.
Allen believes these fears are exaggerated, especially considering CME's low retail exposure and its index licenses in equity products. The consensus among analysts is generally positive, with 8 out of 17 recommending a buy or strong buy on the stock, indicating confidence in CME's recovery despite current challenges